A leap into the future of healthcare: where innovation meets capital
In the dynamic landscape of private markets, the MedTech sector is emerging as fertile ground for high-potential investments, attracting the attention of venture capitalists and private equity managers. The intersection of technological innovation and healthcare is redefining the way we prevent, diagnose, and treat disease, offering unprecedented opportunities for those who know how to make the right bets. From advanced therapies to wearable devices, the wave of digital transformation is permeating every aspect of care, promising a more efficient and personalized future.
Numbers that shape tomorrow: an overview of MedTech investments in Italy and Europe
The global MedTech sector has shown remarkable resilience, with extremely promising venture capital investments. After the first nine months of 2025, medtech companies had raised $12 billion from VC funds across 647 deals. The level of activity puts the sector on course to beat the deal value from 2024, when VCs invested $14 billion in medtech companies (Pitchbook, nov 2025).
Regarding the Italian market, the VeM first-half 2025 report (Intesa Sanpaolo Innovation Center, July 2025) highlights that, out of the 523 million euros raised by startups overall, the healthcare sector proved to be a driving force, confirming its second-place position with a share of 14%.
Radar focused on Italian excellence: MedTech startups you can’t miss
The Italian ecosystem is pulsating with innovation, and several MedTech startups deserve a place of honor in the portfolio of any forward-thinking investor:
ALKemist Bio (Turin): a cutting-edge startup developing next-generation T-cell therapies to combat aggressive ALK-positive cancers. It raised €6.9 million in 2023, demonstrating the potential of its oncology solutions.
MgShell (Milan): specializes in innovative technologies for the treatment of eye diseases. It closed a €1.14 million investment round in April 2025, accelerating preclinical development and market entry.
Genespire (Milan): a company focused on gene therapy. It secured a Series B round of $52 million in September 2024, bringing its total funding to $69.3 million.
Sibylla Biotech (Bresso): an AI-powered platform for drug discovery, focusing on oncology and inflammatory diseases, using the PPI-FIT approach to identify active molecules.
CuraMe: Selected for the Rubik Garage program in October 2025, this startup is creating a unique ecosystem that connects patients, doctors, and pharmacies on a single platform.
Global vision, local impact: international MedTech companies redefining healthcare
Even beyond our borders, the MedTech buzz is palpable, with startups promising to change the face of medicine:
Kelvin Health (Sofia, Bulgaria): This European startup uses AI thermography to provide rapid, accessible vascular diagnoses without radiation. It was selected for the 2025 cohort of MedTech Innovator, highlighting its potential impact.
Reach Neuro (Pittsburgh, USA): Specializing in post-stroke rehabilitation, this company delivers targeted impulses to the spinal cord to reactivate neural pathways and restore control of the arms and hands. It has joined the American Heart Association’s 2025 accelerator program.
Neubond (London, UK) – a spin-out from Imperial College London that develops wearable devices for post-stroke neuromotor rehabilitation, based on intelligent muscle stimulation and real-time monitoring.
AcuityMD (Boston, USA): The company uses anonymized health data from over 325 million patients to help medical device manufacturers identify appropriate physicians and patients for studies and products.
Robeauté (Paris, France): This Parisian startup is developing millimeter-sized microbots for neurosurgery, with the aim of making brain surgery less invasive by delivering molecules, implanting electrodes, and collecting data.
The future of healthcare speaks MedTech
The MedTech sector, with its relentless drive toward innovation and strong backing from private capital, represents one of the most promising frontiers for investors. The opportunities for significant ROI and contributing to improving global quality of life are immense. The message is clear: the future of health is here, and MedTech companies are its chief architects.
